TrialReach receives £2m from investment round

Octopus has led a £2m investment round into TrialReach, an online platform connects patients with healthcare companies and research organisations to make new treatments available more quickly.

Octopus is investing alongside existing investors Amadeus Capital Partners, which first invested in TrialReach in 2011.

Founded in 2010, TrialReach has successfully developed its platform that helps patients with any medical condition to explore, understand and access thelatest clinical trials anywhere in the world.

TrialReach’s platform provides details of over 70,000 clinical trials that are currently authorised and regulated by health authorities. Information on each clinical trial is provided in a clear and simple way to enable patients and their families to explore and compare all available options and make informed decisions.